NeoStem Featured in WCBS-TV Health Watch Segment on Adult Stem Cells

NEW YORK, March 5 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS),
which is pioneering the pre-disease collection, processing and long-term
storage of adult stem cells for future medical need, today announced that
Robin Smith, MD, MBA, and NeoStem's Chairman and Chief Executive Officer was
featured in a WCBS-TV Health Watch segment on adult stem cells.
The Health Watch segment discussed the tremendous promise of adult stem
cells as therapies for a variety of diseases and highlighted several early
clinical successes in certain auto-immune and cardiac disorders. Dr. Smith
shared NeoStem's role in the adult stem cell market through the Company's
safe, and non-invasive method of collecting and storing adult stem cells from
healthy individuals for their own use in the future.
The segment may be viewed online at:
http://wcbstv.com/video/?id=110029@wcbs.dayport.com.

About NeoStem, Inc.
NeoStem is managing a growing nationwide network of adult stem cell
collection centers, enabling people to donate and store their own (autologous)
stem cells when they are young and healthy for their personal use in times of
future medical need. The Company has also recently entered the research and
development and therapeutic arenas, through the acquisition of a worldwide
exclusive license to an early-stage technology to identify and isolate rare
stem cells from adult human bone marrow, called VSELs (very small
embryonic-like stem cells), which have been shown to have several physical
characteristics that are generally found in embryonic stem cells.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements concerning the ability of NeoStem, Inc. ("the
Company") to develop the adult stem cell business, to develop the VSEL
technology, the future of regenerative medicine and the role of adult stem
cells and VSELs in that future, the future use of adult stem cells and VSELs
as a treatment option and the potential revenue growth of the Company's
business. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors, which may cause the actual results,
performance or achievements of the Company, or industry results, to be
materially different from any future results, performance, or achievements
expressed or implied by such forward-looking statements. The Company's ability
to enter the adult stem cell arena, its success in such arena and future
operating results are dependent upon many factors, including but not limited
to (i) the Company's ability to obtain sufficient capital or a strategic
business arrangements to fund its expansion plans; (ii) the Company's ability
to build the management and human resources and infrastructure necessary to
support the growth of its business; (iii) competitive factors and developments
beyond the Company's control; (iv) scientific and medical developments beyond
the Company's control; (v) the Company's inability to obtain appropriate state
licenses or any other adverse effect or limitations caused by government
regulation of the business; (vi) whether any of the Company's current or
future patent applications result in issued patents; and (vii) other risk
factors discussed in the Company's periodic filings with the Securities and
Exchange Commission.
Contact:

NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com
www.neostem.com

SOURCE NeoStem, Inc.

Robin Smith, Chief Executive Officer of NeoStem, Inc., +1-212-584-4180,
rsmith@neostem.com